Objectives: The significance of tumor volume (TV) as a predictor of biochemical failure after radical prostatectomy (RP) remains debatable. TV determinants can also entail significant time and cost. Estimating TVs using an asymmetric categorical classification system provides an economical alternative to determining this parameter. We evaluated the prognostic value of an estimated TV in patients undergoing RP in predicting for prostate-specific antigen (PSA) failure.
Methods: We retrospectively reviewed the clinical and pathologic features of 865 patients who underwent RP at our institution from 1991 to 1999. The TV, PSA level, final Gleason score, percentage of positive biopsy cores, and clinical stage were evaluated using univariate and multivariate analysis to determine their association with biochemical failure. Patients were also stratified according to PSA level (less than versus greater than 10 ng/mL), Gleason score (less than versus greater than 7), and clinical T stage (Stage T1c or better versus worse than Stage T1c) to analyze the prognostic significance of TV in this subpopulation of patients.
Results: Of our 865 evaluable patients, 124 (14.3%) had progression to biochemical failure at a mean follow-up of 60 months. The TV was significantly associated with biochemical failure on univariate analysis (P = 0.024). In the low-risk patients (PSA level less than 10 ng/mL, Gleason score less than 7, and clinical Stage T1c or better), a minimal TV was associated with a lower risk of biochemical failure on multivariate analysis (hazard ratio 2.0, 95% confidence interval 1.09 to 3.68, P = 0.025).
Conclusions: In RP patients with favorable clinical and pathologic characteristics, a minimal TV was associated with a decreased risk of biochemical failure. In carefully selected patients, the estimated TV might provide additional prognostic information for risk stratification for PSA progression and biochemical failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2007.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of key physiological parameters on cardiovascular disease and osteoporosis risk in perimenopausal and postmenopausal women.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, P.R. China.
The essential cause of menopause is ovarian failure, which can cause decline in sex hormones (especially estrogen) that can increase the risk of metabolic diseases, such as cardiovascular disease and osteoporosis. This study screened 1511 eligible patients from 2148 perimenopausal and postmenopausal women, measuring various physiological and biochemical indicators to analyze differences among age groups (40-44, 45-49, and 50-54 years) with laboratory techniques. The study found no significant difference in the incidence of cardiovascular disease betweenperimenopausal and postmenopausal women.
View Article and Find Full Text PDFThe effects of ultra-selective beta1-antagonism on the metabolic and cytokine profile in septic shock patients receiving noradrenaline: a sub-investigation from the STRESS-L Randomised Study.
Intensive Care Med Exp
January 2025
Department of Life Sciences, Aberystwyth University, Ceredigion, UK.
Purpose: The landiolol and organ failure in patients with septic shock (STRESS-L study) included a pre-planned sub-study to assess the effect of landiolol treatment on inflammatory and metabolomic markers.
Methods: Samples collected from 91 patients randomised to STRESS-L were profiled for immune and metabolomic markers. A panel of pro- and anti-inflammatory cytokines were measured through commercially acquired multiplex Luminex assays and statistically analysed by individual and cluster-level analysis (patient).
Fulminant immune checkpoint inhibitor-associated myocarditis bridged to recovery with a temporary left ventricular assist device: a case report.
Eur Heart J Case Rep
January 2025
Cardiology Department, Loyola University Medical Center, 2160 S 1st Ave, Maywood, IL 60153-3328, USA.
Background: Immune checkpoint inhibitors (ICIs) are effective antineoplastic agents but can cause adverse effects in many organ systems. Cardiovascular toxicities include arrhythmias, myocarditis, heart failure, takotsubo syndrome, pericarditis, coronary artery disease, and vasculitis.
Case Summary: A 66-year-old woman with Stage 3C2 endometrial carcinoma presented for her second cycle of pembrolizumab, carboplatin, and paclitaxel.
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants.
Prostate Cancer Prostatic Dis
January 2025
Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Men with pathogenic BRCA1/2 variants are at higher risk of prostate cancer We included men with likely pathogenic/pathogenic (LP/P) variants in BRCA1/2 in a prostate-specific antigen (PSA) screening program after cascade germline testing since 2014. PSA was tested yearly and an age-specific low PSA threshold for biopsy was used, to determine if a low PSA threshold for biopsy is justified for men with pathogenic BRCA1/2 variants.
Methods: From 2014 to 2023 a total of 340 men were included in the program.
[Treatment algorithm following first-line therapy failure in metastatic prostate cancer].
Urologie
January 2025
Klinik für Urologie, Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland.
This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy. Although significant progress has been made in the primary treatment of hormone-sensitive prostate cancer, the management of mCRPC remains a clinical challenge. The article outlines the diagnostic criteria for mCRPC, which can be confirmed through biochemical progression and imaging techniques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!